8:30-9:00 – Plenary lecture
Jürgen Götz (Australia)Tau biology, tau vaccines and therapeutic ultrasound
9:00-11:00 – Session 4 – Tau aggregation (L Serpell & Y Fichou)
- 9:00 – Eckhard Mandelkow (G) Recent insights into Tau seeding and phosphorylation
- 9:15 – Louise Serpell (UK) Phase separation of a paired-helical filament forming region of tau
- 9:25 – Yann Fichou (F) Mutations in tau protein influence aggregation propensity through conformation modulation
- 9:35 – Claudio Gomes (P) Chaperone modulation of tau aggregation and condensation
- 9:45 – Maria Cacho Barraza (UK) Hydromethylthionine first, rivastigmine second: cognitive effects of single versus combination therapies in tau transgenic mice
- 9:55 – Richard McKenney (USA) Oligomerization of Tau on Microtubules
- 10:05 – Alessia Santambrogio (UK) A brain-seeded fibril amplification models the aggregation process of tau in Alzheimer’s disease for drug discovery
- 10:15 – Nicolò Bisi (F) Methods to assess the activity of drug candidates on tau aggregation and tau microtubule dynamics
- 10:25 – Kapil V. Ramachandran (USA) A new mechanism of endogenous Tau aggregation through ApoE / neuro-proteasome complexes
- 10:35 – Questions
10:50-11:20 Coffee break
11:20-13:00 Session 5 – Tau toxicity (M Gratuze & P Dourlen)
- 11:20 – Maria Elena Avale (Arg) Local tau reduction rescues pathological phenotypes in a preclinical model of tauopathy
- 11:30 – Maud Gratuze (F) TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4
- 11:45 – Stephanie Fowler (UK) Short tau filaments are packaged into extracellular vesicles in AD brain
- 11:55 – Pierre Dourlen (F) Presynaptic toxicity of the AD risk gene Bin1
- 12:05 – Lovesha Sivanantharajah (UK) Neuronal vulnerability to tau-mediated toxicity is characterized by a broad spectrum of varying responses
- 12:15 – Katerina Papanikolopoulou (Gr) Mical modulates Tau toxicity via cysteine oxidation in vivo
- 12:25 – Patrik Verstreken (B) Tau toxicity at the synapse
- 12:40 – Questions
12:55-14:15 Lunch & Poster exhibition
14:15-15:40 Session 6 (Chairs: C. Panzi & I. Sotiropoulos)
- 14:15 – Illana Gozes (Israel) Protection against tauopathy is influenced by sex
- 14:25 – Ioannis Sotiropoulos (Gr/P) Persistent pain causes Tau-mediated hippocampal malfunction and memory deficits
- 14:35 – Geoffrey Canet (Ca) Tau secretion is driven by circadian variations of body temperature during the sleep/wake cycle: implications for tau spreading in Alzheimer’s disease
- 14:45 – Chiara Panzi (UK) Investigating the synaptic mechanisms of the spread of wild type and P301S 1N4R human tau in in vitro and in vivo models
- 14:55 – Florent Sauvé (F) A direct CSF-to-blood Tau transport: the tanycytic clearance.
- 15:05 – Daniel Chain (USA) High amount and fast production of tauC3 in PS19 mice
- 15:15 – Rayane Hedna (F) New Thiazole-Flavone Hybrid Compounds Binding to Tau Protein and With Antitumor Activity Against Glioblastoma
- 15:25 -Questions
15:40-16:15 Coffee break
16:15-17:30 Session 7 – Tau therapy (I Dewachter & JP Brion)
- 16:15 – Ilse Dewachter (Belgium) ApoE, inflammation and tau in AD: a road towards multi-targeted therapies
- 16:30 – Claude Wischik (UK) Phase 3 outcomes for tau aggregation inhibitor in Alzheimer’s
- 16:45 – Isabel Lastres Becker (Sp) Neuroprotective effects of CB2 cannabinoid receptor antagonists’ treatment in TAU-dependent Frontotemporal Dementia
- 16:55 – Dina Rodrigues Martins (B) Targeting intracellular tau with intrabodies
- 17:05 – Philippe Verwaerde (France) AZP2006 Phase2a in Progressive Supranuclear Palsy patients
- 17:15 – Questions
17:30 Poster prize and farewell